Program
The scientific program is finalized and can be downloaded as pdf.
Please use the download link at the right side of the webpage.
Please use the download link at the right side of the webpage.
We proudly announce the following outstanding list of speakers:
- NS5A targeted antivirals
Min Gao, Ph.D, Bristol-Myers Squibb, USA
- The Chimpanzee Model of HCV and Preclinical Antiviral Testing
Robert Lanford, Ph.D., Southwest Foundation for Biomedical Research, USA
- Drug Resistance to HCV DAAs: Impact on HCV Therapies
Isabel Najera, Ph.D., Roche, USA
- Development HCV protease inhibitors
Ron. Ralson, Ph.D., Merck Research Laboratories
- The biology of Interferon-lambda in the context of a viral infection
Søren Riis Paludan, DMSc, Ph.D., University of Aarhus, Denmark
- Clinical considerations (re)starting treatment
Michael Fried, M.D., UNC School of Medicine, USA
Confirmed Invited Speakers Joint Session (Morning 24 June):
- The epidemic of HCV; globally and on genotype level. How does maturation of the HCV infected patient population (after 2015) impact drug development?
Gary Davis, M.D., Baylor University Medical Centre, USA
- Dynamics of resistance and the implications for drug development.
Jean-Michel Pawlotsky, M.D., Ph.D., Hôpital Henri Mondor, Université Paris XII, France
- New findings in HCV replication and how to apply to potential antiviral targets
Charles Rice, Ph.D., Rockefeller University, USA
- Implications of genetic host polymorphism for HCV drug developmen and patient care
Mark Sulkowski, M.D., Ph.D., Johns Hopkins University, USA
